Missling has always stated that they will become big Pharma and partner Alzheimer’s, and Parkinson’s and keep the rare disease business for themselves.
True--but the ultimate course was always doing to require approval of the BOD and that point can now be underlined with an independent chairperson. Dr. Missling's role in these matters has now definitively been established as that of a participant, not an ultimate decision maker. That is nothing but good.